BR112016019733A2 - - Google Patents
Info
- Publication number
- BR112016019733A2 BR112016019733A2 BR112016019733A BR112016019733A BR112016019733A2 BR 112016019733 A2 BR112016019733 A2 BR 112016019733A2 BR 112016019733 A BR112016019733 A BR 112016019733A BR 112016019733 A BR112016019733 A BR 112016019733A BR 112016019733 A2 BR112016019733 A2 BR 112016019733A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1403536.4A GB201403536D0 (en) | 2014-02-28 | 2014-02-28 | Inhibitor compounds |
| GB1403536.4 | 2014-02-28 | ||
| PCT/GB2015/050590 WO2015128676A1 (en) | 2014-02-28 | 2015-02-27 | N2-phenyl-pyrido[3,4-d]pyrimidine-2,8-diamine derivatives and their use as mps1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016019733A2 true BR112016019733A2 (US07935481-20110503-C00024.png) | 2017-08-15 |
| BR112016019733B1 BR112016019733B1 (pt) | 2022-12-20 |
Family
ID=50490546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016019733-0A BR112016019733B1 (pt) | 2014-02-28 | 2015-02-27 | Composto derivado de n2-fenil-pirido[3,4-d]pirimidina-2,8-diamina, composição farmacêutica, uso de um composto para a manufatura de um medicamento para tratar um distúrbio proliferativo, e, método para sintetizar um composto |
Country Status (11)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| LT3546458T (lt) * | 2016-11-28 | 2021-05-10 | Teijin Pharma Limited | ((piridin-2-il)-amino)pirido[3,4-d]pirimidino ir ((piridazin-3-il)-amino)pirido[3,4-d]pirimidino dariniai, kaip cdk4/6 inhibitoriai, skirti gydymui, pvz. reumatoidinio artrito, arteriosklerozės, plaučių fibrozės, smegenų infarkto arba vėžio |
| CA3041854A1 (en) * | 2016-11-28 | 2018-05-31 | Teijin Pharma Limited | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof |
| GB201709840D0 (en) * | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| US20200171032A1 (en) * | 2017-06-20 | 2020-06-04 | The Institute Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| GB201809458D0 (en) | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| GB201809460D0 (en) | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| BR112021017829A2 (pt) * | 2019-03-13 | 2021-11-30 | Voronoi Inc | Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer |
| JP7236204B2 (ja) | 2019-06-28 | 2023-03-09 | ダイハツ工業株式会社 | コンソールボックス |
| CN115385840B (zh) * | 2022-09-05 | 2024-07-02 | 北京京宇复瑞科技集团有限责任公司 | 制备3-甲氧基氮杂环丁烷盐酸盐的方法 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2697710A (en) | 1953-01-02 | 1954-12-21 | Burroughs Wellcome Co | Pyrido (2,3-d) pyrimidines and method of preparing same |
| US3021332A (en) | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
| TJ342B (en) | 1994-11-14 | 2002-10-06 | Warner Lambert Co | Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
| CA2244897C (en) | 1996-03-05 | 2006-04-11 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
| EA200200643A1 (ru) | 2000-01-25 | 2002-12-26 | Уорнер-Ламберт Компани | ПИРИДО[2,3-d]ПИРИМИДИН-2,7-ДИАМИНОВЫЕ ИНГИБИТОРЫ КИНАЗ |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153325A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| AU2002324450A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidines and uses thereof |
| CA2470214A1 (en) | 2001-12-13 | 2003-06-26 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| DE60323946D1 (de) | 2002-03-07 | 2008-11-20 | Hoffmann La Roche | Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase |
| US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
| CA2505427C (en) | 2002-11-12 | 2012-04-03 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
| BRPI0406809A (pt) | 2003-01-17 | 2005-12-27 | Warner Lambert Co | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular |
| JP4189492B2 (ja) | 2004-03-22 | 2008-12-03 | 独立行政法人物質・材料研究機構 | 層状複水酸化物／ゼオライト複合体 |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| BRPI0613597A2 (pt) | 2005-06-28 | 2011-01-18 | Sanofi Aventis | derivado de isoquinolina como inibidores de rho-quinase |
| TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| BRPI0720563A2 (pt) | 2006-12-22 | 2014-02-04 | Novartis Ag | Quinazolinas para inibição de pdk1 |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| EA201000341A1 (ru) * | 2007-08-23 | 2010-10-29 | Астразенека Аб | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| JPWO2009084695A1 (ja) | 2007-12-28 | 2011-05-19 | カルナバイオサイエンス株式会社 | ２−アミノキナゾリン誘導体 |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| RU2581367C2 (ru) | 2010-03-01 | 2016-04-20 | Джи Ти Икс, ИНК. | Соединения для лечения рака |
| EP2598508B1 (en) | 2010-07-30 | 2015-04-22 | Nerviano Medical Sciences S.r.l. | Isoxazolo-quinazolines as modulators of protein kinase activity |
| ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
| JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| EP2651899B1 (en) | 2010-12-17 | 2017-05-31 | F. Hoffmann-La Roche AG | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| US8883793B2 (en) | 2010-12-29 | 2014-11-11 | Development Center For Biotechnology | Tubulin inhibitors and methods of using the same |
| EP2668190B1 (en) * | 2011-01-26 | 2016-08-17 | Nerviano Medical Sciences S.r.l. | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| US9745191B2 (en) | 2011-04-11 | 2017-08-29 | Saudi Arabian Oil Company | Auto thermal reforming (ATR) catalytic structures |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP5928960B2 (ja) | 2013-06-04 | 2016-06-01 | 国立大学法人佐賀大学 | イオン吸着材の製造方法 |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
-
2014
- 2014-02-28 GB GBGB1403536.4A patent/GB201403536D0/en not_active Ceased
-
2015
- 2015-02-27 WO PCT/GB2015/050590 patent/WO2015128676A1/en active Application Filing
- 2015-02-27 CN CN201580010416.4A patent/CN106459035B/zh active Active
- 2015-02-27 ES ES19173169T patent/ES2926641T3/es active Active
- 2015-02-27 EP EP19173169.4A patent/EP3575299B1/en active Active
- 2015-02-27 BR BR112016019733-0A patent/BR112016019733B1/pt active IP Right Grant
- 2015-02-27 JP JP2016554566A patent/JP6440728B2/ja not_active Expired - Fee Related
- 2015-02-27 CA CA2939058A patent/CA2939058C/en active Active
- 2015-02-27 US US15/121,432 patent/US9902721B2/en active Active
- 2015-02-27 ES ES15707759T patent/ES2739148T3/es active Active
- 2015-02-27 AU AU2015221956A patent/AU2015221956B2/en not_active Ceased
- 2015-02-27 RU RU2016137789A patent/RU2693460C2/ru active
- 2015-02-27 EP EP15707759.5A patent/EP3110816B1/en active Active
-
2018
- 2018-01-03 US US15/861,287 patent/US10399974B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016137789A (ru) | 2018-04-03 |
| JP6440728B2 (ja) | 2018-12-19 |
| US9902721B2 (en) | 2018-02-27 |
| EP3110816B1 (en) | 2019-06-19 |
| AU2015221956B2 (en) | 2019-05-09 |
| US10399974B2 (en) | 2019-09-03 |
| EP3110816A1 (en) | 2017-01-04 |
| EP3575299B1 (en) | 2022-07-20 |
| ES2926641T3 (es) | 2022-10-27 |
| EP3575299A1 (en) | 2019-12-04 |
| US20180194761A1 (en) | 2018-07-12 |
| CN106459035B (zh) | 2018-04-06 |
| RU2693460C2 (ru) | 2019-07-03 |
| US20160362409A1 (en) | 2016-12-15 |
| JP2017506661A (ja) | 2017-03-09 |
| CA2939058C (en) | 2022-04-26 |
| AU2015221956A1 (en) | 2016-07-07 |
| RU2016137789A3 (US07935481-20110503-C00024.png) | 2018-10-23 |
| ES2739148T3 (es) | 2020-01-29 |
| BR112016019733B1 (pt) | 2022-12-20 |
| WO2015128676A1 (en) | 2015-09-03 |
| CA2939058A1 (en) | 2015-09-03 |
| GB201403536D0 (en) | 2014-04-16 |
| CN106459035A (zh) | 2017-02-22 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2015, OBSERVADAS AS CONDICOES LEGAIS |